The absolute bioavailability of cefprozil, a new oral cephalosporin, in four beagles was evaluated. In this two-way crossover study, each dog received a 125-mg dose of cefprozil either as an oral aqueous solution or as a 15-min intravenous infusion. A high-performance liquid chromatographic assay with UV detection was employed for the determination of cefprozil concentrations in plasma and urine. Key pharmacokinetic parameters were calculated by noncompartmental methods. Cefprozil was well absorbed after oral administration, and peak concentrations of 17.6 to 26.6 ,ug/ml were attained at 60 min after drug administration. The apparent elimination half-life of cefprozil was about 70 min. The renal clearance was about 60% of total body clearance and is suggestive of significant nonrenal clearance. The absolute bioavailability of cefprozil ranged from 67.1 to 79.1% in the dogs.
Cefprozil is a new oral cephalosporin with an antibacterial spectrum that includes important gram-positive and gramnegative organisms (4, 6) . It is structurally similar to other cephalosporins in that it has a phenylglycine side chain. Cephalosporins with phenylglycine side chains, such as cephalexin and cefadroxil, are almost completely absorbed and undergo minimal metabolism after oral administration (7, 12) . As a result, urinary excretion of these cephalosporins accounts for more than 80% of the administered dose (7, 12) . Cefprozil, like other oral cephalosporins, is also well absorbed after oral administration (1-3) in humans. However, urinary recovery accounts for about 60% of the administered dose of cefprozil (1) (2) (3) . It appears that cefprozil is incompletely absorbed, is metabolized, and/or is eliminated via biliary excretion in humans. The extent of oral absorption of cefprozil in humans is not known at this time. The present two-way crossover study was designed to evaluate absolute bioavailability of orally administered cefprozil in dogs.
In a two-way crossover study, four beagles weighing 8 to 12 kg each were administered a 125-mg dose of cefprozil either as an oral aqueous solution or as a 15-min intravenous infusion. There was a 1-week washout period between treatments. The dosing solution was freshly prepared by dissolving 1,000 mg of cefprozil in 200 ml of sterile water. A solution containing 5 mg of cefprozil per ml was filtered through a 0.22-,um-pore-size filter and administered within 2 h of preparation. Food was withheld for about 12 to 14 h prior to dosing and for 4 h after dosing. For At the end of the 0-to 4-and 4-to 8-h urine collection intervals, the bladders were flushed with two 10-ml portions of sterile water, and the rinsings were combined with the urine samples for the respective collection interval. The 8-to 24-h urine specimens were collected from the metabolism cage in a container which was then placed over dry ice. The total volume of each urine specimen was measured and recorded. A 5.0-ml portion of the urine sample was then transferred to a polypropylene tube containing 5.0 ml of sodium acetate buffer (pH 3.6), mixed, and stored at or below -20°C. Plasma and urine samples were assayed for intact cefprozil by using a validated high-performance liquid chromatographic assay with UV detection (2) . The lower limits for quantitation of cefprozil in plasma and urine were 0.5 and 2.0 ,ug/ml, respectively. The cefprozil standard curves in plasma and urine were linear within the 0.5-to 30-and 2.0-to 500-,ug/ml ranges, respectively. Quality control samples, containing known concentrations of cefprozil, were prepared prior to the initiation of the study. These quality control samples were stored with the study samples. The within-day coefficients of variation for the quality control sample concentrations of cefprozil in plasma of 5.0 (n = 5) and 20 (n = 5) ,ug/ml were less than 8.56%, where n is the number of replicates of quality control samples. The withinday coefficients of variation for the quality control sample concentrations of cefprozil in urine of 50 (n = 5) and 250 (n = 5) ,ug/ml were less than 6.8%. Excellent data for accuracy and a coefficient of variation consistently less than 9.0% for the quality control samples suggest that the assays for cefprozil in plasma and urine were accurate and precise and that cefprozil was stable in the study samples during storage.
The following pharmacokinetic parameters were calculated for each dog by using standard techniques (5, The mean concentration-versus-time profiles of cefprozil in plasma after intravenous and oral administration are shown in Fig. 1 . Key pharmacokinetic parameters for cefprozil are shown in Table 1 . Following oral administration, cefprozil reached a Cmx of 17.6 to 26.6 ,ug/ml within 60 min after administration, and measurable concentrations of cefprozil were found at 8 h postdose, which was the time of the last collected sample. The mean absorption time for orally administered cefprozil ranged from 42 to 104 min. Cefprozil levels declined, with an apparent elimination half-life of about 69 to 104 min. The value for the steady-state volume of distribution was about 0.2 liters/kg, indicating that cefprozil was distributed mainly in body water. The renal clearance of cefprozil was approximately 60% of the total body clearance, suggesting that nonrenal clearance plays a significant role in clearing cefprozil from dogs. The majority of cefprozil was excreted in urine during the 0-to 4-h collection period, regardless of the route of administration. Cefprozil was not detectable in the 8-to 24-h urine samples. Overall, 60.9 and 39.5% of the dose was recovered after intravenous and oral administration, respectively. The absolute bioavailability of cefprozil ranged from 67.1 to 79.1% in the four dogs.
Oral cephalosporins with a phenylglycine side chain are completely absorbed after oral administration and are excreted primarily in an unchanged form in urine (8) (9) (10) . The data from the present study with dogs indicate that the absolute bioavailability of cefprozil after oral administration is about 70% and that only 40% of the dose is recovered in urine as intact cefprozil. These data suggest that cefprozil may not be completely absorbed or may be subjected to biliary excretion or presystemic metabolism in dogs. The unabsorbed fraction of an orally administered broad-spectrum antibiotic can disturb the microbial flora of the gastrointestinal tract and can cause gastrointestinal discomfort and diarrhea. Assessment of absolute bioavailability of oral antibiotics is therefore very important. The absolute bioavailability of oral cephalosporins such as cephalexin, cefadroxil, cephradine, and ceftrazine (9, 10) is greater than 90% and suggests complete absorption in humans. Our data suggest that the absolute bioavailability of cefprozil in dogs is lower than that reported for other oral cephalosporins in humans. Although urinary recovery of cefprozil following oral administration in humans (60 to 70%) is significantly higher (1) (2) (3) than that observed in dogs (40%), the data from this study raise a need to evaluate the fraction of the orally administered dose absorbed and the absolute bioavailability of this new oral cephalosporin in humans.
